Lexeo Therapeutics (LXEO) Net Cash Flow (2022 - 2026)

Lexeo Therapeutics has disclosed Net Cash Flow across 5 years of filings, most recently posting $8.8 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at $8.8 million, up 243.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $42.9 million (up 125.79% YoY), and the FY2025 annual result was $28.0 million, up 132.37% from the prior year.
• Net Cash Flow came in at $8.8 million for Q1 2026 at Lexeo Therapeutics, down from $22.0 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $86.0 million in Q4 2023 to a low of -$122.0 million in Q4 2024.
• The 5-year median for Net Cash Flow is -$8.1 million (2023), against an average of -$1.6 million.
• Across the five-year window, Net Cash Flow jumped 611.58% in 2023 and sank 241.84% in 2024, its largest moves.
• Lexeo Therapeutics' Net Cash Flow stood at -$16.8 million in 2022, then surged by 611.58% to $86.0 million in 2023, then tumbled by 241.84% to -$122.0 million in 2024, then surged by 118.04% to $22.0 million in 2025, then sank by 60.15% to $8.8 million in 2026.
• The last three Net Cash Flow figures came in at $8.8 million (Q1 2026), $22.0 million (Q4 2025), and $5.5 million (Q3 2025), per Business Quant data.